NanoBio Presents Positive Results From Nanoemulsion Vaccine Study

NanoBio has presented positive results from the studies in mice in which immune responses were evaluated following administration of 5µg doses of recombinant H5N1 flu antigen combined with the company’s nanoemulsion vaccine.

The adjuvant was administered for the first time by subcutaneous (SC) and intramuscular (IM) injections. The mice that received either SC or IM H5 antigen combined with nanoemulsion had maximal immune responses at least a 1000 fold higher than control animals that received the same antigen IM without the nanoemulsion adjuvant.

NanoBio’s nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases, said the company.

NanoBio’s underlying technology is NanoStat platform, which employs a nanoemulsion that is created through a proprietary manufacturing process. The nanoemulsion has proven to be capable of permeating the nasal mucosa, where it can load vaccine antigen into immune-presenting cells.

The company’s NanoStat adjuvant platform technology has demonstrated numerous potential advantages over traditional vaccines, including the ability to generate robust mucosal, systemic and cellular immunity, antigen-sparing qualities, cross-protection against non-vaccinated strains, ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilising the vaccine; and removing the need for needles.

James Baker, founder and CEO of NanoBio, said: “It is encouraging that these strong immune responses were achieved without evidence of significant irritation or inflammation, which could differentiate these IM vaccines from currently approved IM adjuvants.

“These new data further demonstrate the broad safety and potential universal applicability of NanoBio’s vaccine adjuvant platform for immunisation in a method most appropriate for the particular disease.”